← SynDRA
ORITAVANCIN
SynDRA canonical compound SYN0026427 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Mechanism of action | bacterial cell wall synthesis inhibitor |
|---|
| Indication | skin infections |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- bacterial cell wall synthesis inhibitor
- Bact folP INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anti-Bacterial Agents
- Anti-Infective Agents
- Cytochrome P450 2C19 Inhibitors
- Cytochrome P450 2C9 Inhibitors
- Cytochrome P450 3A4 Inducers
- Cytochrome P450 2D6 Inducers
- Lipoglycopeptide Antibacterial
ATC classes
- J01X · OTHER ANTIBACTERIALS
Cross-references
Synonyms
- KIMYRSA
- Kimyrsa
- ORBACTIV
- Orbactiv
- oritavancin diphosphate
- orbactiv
- LY333328
- Oritavancine
- Oritavancina
- LY-333328
- Nuvocid
- Oritavancin [INN]
- Chlorobiphenyl-chloroeremomycin
- LY 333328
- PUG62FRZ2E
- oritavancina
- oritavancine
- CHEBI:82699
- oritavancinum
- oritavacin diphosphate
- RefChem:57173
- J01XA05
- DTXCID701326917
- UNII-PUG62FRZ2E
- Orita-vancin
- C12034
- ORITAVANCIN [MI]
- ORITAVANCIN [VANDF]
- ORITAVANCIN [MART.]
- ORITAVANCIN [WHO-DD]
- Oritavancin(LY-333328)
- Oritavancin; LY-333328
- orb1692501
- SCHEMBL9947049
- SCHEMBL29416865
- GTPL10877
- VHFGEBVPHAGQPI-LXKZPTCJSA-N
- BDBM513037
Reported adverse events
- Dizziness
- Hypersensitivity
- Nausea
- Vomiting
- Abscess
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Headache
- Osteomyelitis
- Tachycardia
- Infusion site phlebitis
- Infusion site reaction
Look up ORITAVANCIN in the interactive SynDRA portal →